拉帕替尼联合化疗治疗晚期乳腺癌的效果及对无进展生存期的影响  

Effect of Lapatinib Plus Chemotherapy for Advanced Breast Cancer and Effect on Progression-free Survival

作　　者：伊雪飞 郭建平[1] YI Xuefei;GUO Jianping(Department of Oncology,Zibo Maternal and Child Health Care Hospital,Zibo 255000,Shandong,China)

机构地区：[1]淄博市妇幼保健院肿瘤科,山东淄博255000

出　　处：《系统医学》2025年第1期17-20,共4页Systems Medicine

基　　金：淄博市妇幼保健院医院发展基金(202106078)。

摘　　要：目的分析晚期乳腺癌患者使用拉帕替尼联合化疗治疗的效果及对远期预后的影响。方法非随机选取2022年6月—2023年6月淄博市妇幼保健院肿瘤科收治的56例晚期乳腺癌患者为研究对象,按治疗方案分为两联组和三联组,每组28例。两联组给予常规化疗方案(多西他赛+卡铂),三联组在两联组基础上增加拉帕替尼联合治疗。对比两组患者的近期疗效、远期疗效、不良反应发生情况及血清肿瘤标志物水平。结果两组总疗效比较,差异无统计学意义(P>0.05)。三联组无进展生存期、总生存期时间分别为(11.86±0.43)个月、(13.01±2.42)个月,长于两联组的(6.69±1.46)个月、(11.89±0.76)个月,差异有统计学意义(t=17.974、2.336,P均<0.05)。两组患者化疗期间不良反应发生率比较,差异无统计学意义(P>0.05)。三联组血清肿瘤标志物水平优于两联组,差异有统计学意义(P均<0.05)。结论拉帕替尼联合化疗治疗晚期乳腺癌患者,可取得较佳疗效,控制疾病发展进程。Objective To analyze the effect of treatment with lapatinib in combination with chemotherapy in patients with advanced breast cancer and its impact on long-term prognosis.Methods Fifty-six patients with advanced breast cancer admitted to the oncology department of Zibo Maternal and Child Health Care Hospital from June 2022 to June 2023 were non-randomly selected as the study subjects,and were divided into the two-link group and the three-link group according to the treatment regimens,with twenty-eight cases in each group.The two-link group was given con⁃ventional chemotherapy program(docetaxel+carboplatin),and the three-link group added lapatinib combination therapy on the basis of the two groups.The recent efficacy,long-term efficacy,adverse reactions and serum tumor marker levels of patients in the two groups were compared.Results There was no statistically significant difference in overall efficacy between the two groups(P>0.05).The progression-free survival and overall survival time of the three-link group were(11.86±0.43)months and(13.01±2.42)months,respectively,which were longer than those of the two-link group(6.69±1.46)months and(11.89±0.76)months,and the differences were statistically significant(t=17.974,2.336,both P<0.05).There was no statistically significant difference in the incidence of adverse reactions during che⁃motherapy between the two groups(P>0.05).The serum tumor marker levels in the three-link group were better than those in the two-link group,and the differences were statistically significant(all P<0.05).Conclusion Lapatinib in combination with chemotherapy for the treatment of patients with advanced breast cancer can achieve better efficacy and control the disease progression.

关 键 词：晚期乳腺癌 化疗 拉帕替尼 无进展生存期 

分 类 号：R737.9[医药卫生—肿瘤]